Follow-up of implantable cardioverter-defibrillator therapy: Comparison of coronary artery disease and dilated cardiomyopathy

Netherlands Heart Journal

Volumn 22, Issue 10, 2014, Pages 431-437

  Verhagen, M P ^a   van Boven, N ^a   Ruiter, J H ^a   Kimman, G J P ^a   Tahapary, G J ^a   Umans, V A ^a  

^a Location Alkmaar   (Netherlands)

Author keywords

Coronary artery disease; Dilated cardiomyopathy; Implantable cardioverter defibrillator; Systolic dysfunction

Indexed keywords

AMIODARONE; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOGENIC SHOCK; CATHETER ABLATION; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; QRS COMPLEX; QUALITY OF LIFE; SMOKING; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL TIME; SYSTOLIC DYSFUNCTION;

EID: 84908018176     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-014-0595-z     Document Type: Article

References (29)

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933-40.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
4. HuaW, Niu H, Fan X, et al. Preventive Effectiveness of Implantable Cardioverter Defibrillator in Reducing Sudden Cardiac Death in the Chinese Population:AMulticenter Trial of ICD Therapy versus Non- ICD Therapy. J Cardiovasc Electrophysiol. 2012;23 Suppl 1:s5-9.
5. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks inMADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357-65.
6. Powell BD, Asirvatham SJ, Perschbacher DL, et al. Noise, artifact, and oversensing related inappropriate ICD shock evaluation: ALTITUDE noise study. Pacing Clin Electrophysiol. 2012;35:863-9.
7. Gradaus R, Block M, Brachmann J, et al. Mortality, morbidity, and complications in 3344 patients with implantable cardioverter defibrillators: results from the German ICD Registry EURID. Pacing Clin Electrophysiol. 2003;26:1511-8.
8. Schaer B, Kuhne M, Koller MT, et al. Therapy with an implantable cardioverter defibrillator (ICD) in patients with coronary artery disease and dilated cardiomyopathy: benefits and disadvantages. Swiss Med Wkly. 2009;139:647-53.
9. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: an European analysis. Eur Heart J. 2012;34:211-9.
10. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:746-837.
11. Cygankiewicz I, Gillespie J, Zareba W, et al. Predictors of long-term mortality inMulticenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. Heart Rhythm. 2009;6:468-73.
12. Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a metaanalysis of randomized controlled trials. JAMA. 2003;289:730-40.
13. Wissner E, Stevenson WG, Kuck KH. Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical review. Eur Heart J. 2012;33:1440-50.
14. Streitner F, Kuschyk J, Dietrich C, et al. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention. Clin Cardiol. 2011;34:604-9.
15. Ermis C, Zhu AX, Vanheel L, et al. Comparison of ventricular arrhythmia frequency in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy treated with implantable cardioverter defibrillators. Am J Cardiol. 2005;96:233-8.
16. Gandhi K, Aronow WS, Desai H, et al. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up. Arch Med Sci. 2010;6:900-3.
17. Smith T, Theuns DA, Caliskan K, et al. Long-term follow-up of prophylactic implantable cardioverter-defibrillator-only therapy: comparison of ischemic and nonischemic heart disease. Clin Cardiol. 2011;34:761-7.
18. Sutton MG, Plappert T, Hilpisch KE, et al. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation. 2006;113:266-72.
19. Contractor T, Beri A, Gardiner J, et al. Statins Reduce Appropriate Implantable Cardioverter-Defibrillator Shocks in Ischemic Cardiomyopathy With no Benefit in Nonischemic Cardiomyopathy. Am J Ther. 2012;19:413-8.
20. Beri A, Contractor T, Gardiner JC, et al. Reduction in the intensity rate of appropriate shocks for ventricular arrhythmias with statin therapy. J Cardiovasc Pharmacol. 2010;56:190-4.
21. Obeyesekere MN, Chan W, Stub D, et al. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population. Pacing Clin Electrophysiol. 2010;33:696-704.
22. Dichtl W, Wolber T, Paoli U, et al. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients. Clin Cardiol. 2011;34:433-6.
23. Sanchez JM, Greenberg SL, Chen J, et al. Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population. Heart Rhythm. 2006;3:443-9.
24. Wijers SC, van der Kolk BY, Tuinenburg AE, et al. Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit? Neth Heart J. 2013;21: 274-83.
25. van Rees JB, Borleffs CJ, de BieMK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011;57:556-62.
26. Vollmann D, Luthje L, Vonhof S, et al. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2:307-9.
27. Kraaier K, Starrenburg AH, Verheggen RM, et al. Incidence and predictors of phantomshocks in implantable cardioverter defibrillator recipients. Neth Heart J. 2013;21:191-5.
28. Moss AJ, Schuger C, Beck CA, et al. Reduction in Inappropriate Therapy and Mortality through ICD Programming. N Engl J Med. 2012;13(367):2275-83.
29. Wilkoff BL,Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverterdefibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541-50.